Exemestane (Aromasin®)
How does this drug work?
Exemestane is a hormonal drug that prevents the growth of breast cancer by inhibiting the enzyme aromatase, which is involved in the production of estrogen. Exemestane significantly lowers the amount of estrogen in post-menopausal women by inhibiting the conversion of androgens (made in the adrenal glands) to estrogen. It is taken orally in a 25-mg dose daily after a meal. It is currently indicated for postmenopausal women with advanced breast cancer after progression or prior treatment with tamoxifen. It should not be take by premenopausal women.

General Side Effects
Exemestane is generally well tolerated and adverse effects are usually mild to moderate. Only about 3% of women would be expected to discontinue exemestane due to side effects. Late discontinuation of therapy (after 3 months) is uncommon.
Common side effects
- Hot flashes (13%)
- Nausea or vomiting (9%)
- Fatigue (8%)
- Increased Perspiration (4%)
- Increased appetite (3%)
- Weight gain (18%)
- Constipation (6%)
- Pain at tumor site (8%)
- Weakness (6%)
Less common side effects with your type of chemotherapy:
- Drug reaction: difficulty breathing, shortness of breath, flushing, low blood pressure
- Numbness
- Rash
- Back or joint pain
As with any drug, other side effects that were not mentioned may occur

General concerns
- Report vomiting or nausea that is not relieved with anti-nausea medication.
- Immediately report any fevers of 101ƒ or higher, with or without chills.
- Report nose bleeds, gum bleeding, or any unusual bruising.
- Ask your doctor about a birth control method for you.
- Report any symptoms that are unusual for you.
- Report any swelling which is uncomfortable.
- Report any shortness of breath.

During the day, you may reach a doctor or nurse by calling the Breast Care Center Oncology/Chemotherapy number (see phone list).
After hours and on weekends, please be sure to use the specified Oncology/Chemotherapy, as this is the ONLY number to connect you to the appropriate physician on call.